Click here to join our community of experts to get information on job search, salaries and more.

factory
corporate_fare
where_to_vote
paid
Funding Stage -
person
Layoff Count -

Posted on August 15, 2022

ContraFect Cuts Workforce After Trial Setback

ContraFect Cuts Workforce After Trial Setback

  • ContraFect Corporation  said it continues to advance lead programs toward new clinical studies and expects to file with regulatory authorities later this year to initiate a study of intra-articular exebacase in chronic or recurrent prosthetic joint infections. 
  • The company is also completing the GLP toxicology studies required for the IND application of CF-370 for resistant gram-negative infections. It expects to advance CF-370 into clinical development with a multiple-day dose regimen.
  • Last month, Data Safety Monitoring Board recommended that the DISRUPT trial be stopped because the conditional power of the study was below the pre-specified threshold for futility.